The rise and fall in menopausal hormone therapy and breast cancer incidence.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_785ECDF75D01
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The rise and fall in menopausal hormone therapy and breast cancer incidence.
Périodique
The Breast
Auteur(s)
Pelucchi Claudio, Levi Fabio, La Vecchia Carlo
ISSN
1532-3080[electronic], 0960-9776[linking]
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
19
Numéro
3
Pages
198-201
Langue
anglais
Résumé
Studies conducted in different areas of North America and Europe showed a 5-10% decline in the incidence of breast cancer following reductions up to 70% in menopause hormone therapy (HT) use after 2002. The observation that the decline was larger in (or limited to) women aged > or =50 years weighs in favour of an effect of reduced HT use on breast cancer incidence. However, changes in screening are also likely to play a role in the decreasing incidence of breast cancer observed in several countries. In particular, the technical improvements and the increased effectiveness of breast cancer screening and detection during the 1990s led to a decreased number of pre-clinical cases found by screening in subsequent years. Further, disentangling the effects of HT use and screening is difficult, as women who stop using HT may also undergo mammography screening less frequently. Thus, the reasons of the falls in incidence remain open to discussion.
Mots-clé
Aged, Breast Neoplasms/epidemiology, Breast Neoplasms/pathology, Estrogen Replacement Therapy, Female, Humans, Incidence, Middle Aged
Pubmed
Web of science
Création de la notice
24/11/2010 9:55
Dernière modification de la notice
20/08/2019 14:35
Données d'usage